Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

v3.5.0.2
Liquidity (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended
Aug. 31, 2016
Dec. 31, 2015
Jun. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2014
Accumulated deficit   $ 13,277,814   $ 25,706,214    
Gross proceeds from sale of stock       15,235,283 $ 10,819,714  
Cash and cash equivalents   12,338,275   18,909,348 $ 13,172,926 $ 6,262,445
Cystic Fibrosis Foundation Therapeutics Inc [Member]            
Amount received on milestone payment $ 1,000,000 $ 1,250,000   $ 1,500,000    
Securities Purchase Agreement [Member] | Investors [Member]            
Aggregate common stock sold, shares     5,960,000      
Shares issued price per share     $ 2.50      
Gross proceeds from sale of stock     $ 14,875,000